PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930120
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930120
Shingles Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of Shingles Vaccines Market
The global Shingles Vaccines Market demonstrated strong expansion in the base year 2025, driven by rising disease prevalence, increasing geriatric population, and growing awareness regarding preventive adult immunization. According to the report, the market size was valued at USD 5.67 billion in 2025. With continued uptake of advanced vaccines and broader immunization coverage, the market is projected to grow to USD 5.95 billion in 2026 and further expand to USD 12.92 billion by 2034. North America dominated the global landscape with a 36.98% market share in 2025, supported by high awareness levels, strong healthcare infrastructure, and widespread adoption of recombinant shingles vaccines.
Shingles vaccines are used to prevent herpes zoster, a painful and often debilitating condition caused by reactivation of the varicella-zoster virus. The virus remains dormant after an individual recovers from chickenpox and can reactivate later in life, particularly among older adults and immunocompromised populations. Vaccination, administered in a two-dose schedule, remains the only effective preventive measure against shingles and its complications.
Market Dynamics
Market Drivers
The rising incidence of shingles globally is a primary factor driving market growth across 2025 and 2026. Aging populations and immunosenescence significantly increase susceptibility to shingles, resulting in higher vaccine demand. Data published in September 2023 indicated a shingles prevalence rate of 1.2-3.4 cases per 1,000 persons per year among younger healthy adults, with substantially higher rates in older populations. In parallel, increasing awareness campaigns and recommendations from health authorities further boost vaccine adoption.
Market Restraints
Side effects associated with shingles vaccines remain a limiting factor. Adverse reactions such as injection-site pain, fatigue, fever, and rare neurological conditions can affect patient confidence. In 2023, Canada discontinued Zostavax due to safety concerns, highlighting how tolerability issues can influence market dynamics and shift demand toward safer alternatives.
Market Opportunities
Addressing cost barriers represents a major growth opportunity. High vaccine prices and limited insurance coverage restrict uptake in several regions. In February 2025, the cost of two doses of SHINGRIX in India ranged between USD 300-400, limiting accessibility. Price reductions, government subsidies, and reimbursement expansion could significantly improve adoption rates and support market growth toward 2034.
Market Challenges
Limited awareness and restricted access in certain regions challenge market expansion. Studies published in October 2023 showed that while 57.2% of participants were aware of the shingles vaccine in selected populations, only 7.7% had received it. Such gaps in awareness and access continue to hinder optimal vaccine coverage.
Shingles Vaccines Market Trends
A key trend shaping the global market is the increasing adoption of recombinant subunit vaccines. Non-live vaccines such as SHINGRIX are preferred due to their superior efficacy and safety profile, particularly for older and immunocompromised individuals. In July 2024, clinical data confirmed that recombinant vaccines not only prevent shingles but also significantly reduce the risk of postherpetic neuralgia, reinforcing their growing dominance.
Segmentation Analysis
By Type
The recombinant/conjugate/subunit segment dominated the market in 2024 and is expected to register the fastest growth through 2034. These vaccines offer high protection without the risks associated with live attenuated formulations. The "others" segment, including mRNA-based vaccines, is gaining attention, with multiple candidates entering clinical trials.
By Product
The SHINGRIX segment held the largest market share in 2024, supported by strong clinical efficacy. Data published in July 2024 showed SHINGRIX to be 97% effective in preventing shingles among adults aged 50-69 years, reinforcing its leadership position. Pipeline products, including mRNA-based vaccines, form the remainder of the segment.
By Distribution Channel
Government suppliers dominated the market in 2024, driven by national immunization initiatives and favorable reimbursement policies. Hospital and retail pharmacies are expected to maintain significant shares due to increasing public-private partnerships and improved access in urban healthcare settings.
Regional Outlook
North America
North America generated USD 2.10 billion in 2025 and USD 2.16 billion in 2026, driven by high disease prevalence and strong vaccination programs. The U.S. leads the region, with approximately 1 million shingles cases annually, supporting sustained vaccine demand.
Europe
Europe holds the second-largest share, supported by favorable reimbursement frameworks and region-wide awareness initiatives. Collaborative campaigns have strengthened adult vaccination coverage across EU countries.
Asia Pacific
Asia Pacific is the fastest-growing region, supported by rising elderly populations, increasing disposable income, and expanding government-backed immunization efforts. Awareness campaigns by leading manufacturers further support growth.
Latin America and Middle East & Africa
These regions are expected to witness steady growth, driven by improving healthcare access, rising awareness, and gradual introduction of advanced shingles vaccines.
Competitive Landscape
The market is led by GSK plc. and Pfizer Inc., which together account for a significant share. GSK's SHINGRIX remains the most widely adopted product globally, supported by regulatory approvals and awareness initiatives. Pfizer, in collaboration with BioNTech, is advancing mRNA-based shingles vaccines. Other notable players include Moderna Inc., Dynavax Technologies, Jiangsu Recbio Technology Co., Ltd., and Curevo Inc., all actively investing in next-generation vaccine development.
Report Coverage
The shingles vaccines market report provides a comprehensive analysis aligned strictly with 2025, 2026, and 2034 market values. It covers market dynamics, segmentation by type, product, and distribution channel, regional performance, competitive landscape, and key industry developments, offering a detailed view of market evolution across the forecast period.
Conclusion
The global Shingles Vaccines Market exhibits a strong and well-supported growth outlook across the report years, driven by rising shingles incidence, demographic aging, and increasing emphasis on adult preventive immunization. Valued at USD 5.67 billion in 2025, the market reflects growing acceptance of vaccination as the most effective preventive strategy against herpes zoster and its long-term complications. The steady rise to USD 5.95 billion in 2026 highlights continued short-term expansion supported by awareness initiatives, strong government participation, and high adoption of recombinant subunit vaccines, particularly in North America, which accounted for 36.98% of the global market in 2025.
Looking ahead, the projected expansion to USD 12.92 billion by 2034 is underpinned by sustained demand from aging populations, technological advancements in non-live vaccine platforms, and pipeline developments such as mRNA-based shingles vaccines. While challenges related to cost barriers, side effects, and uneven awareness persist across certain regions, increasing government support, reimbursement policies, and public-private collaborations are expected to enhance accessibility and uptake. Overall, the shingles vaccines market is positioned for consistent long-term value growth, maintaining its critical role in adult immunization and preventive healthcare throughout the forecast period.
Segmentation
By Type
- Recombinant/Conjugate/Subunit
- Others
By Product
- SHINGRIX
- Others
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Product, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Product, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Product, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- o
- Rest of Asia Pacific
- Latin America (By Type, Product, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, Product, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Epidemiology of Shingles (Herpes Zoster)
- 4.2. Reimbursement Scenario, By Key Countries/Regions
- 4.3. Pipeline Analysis, By Key Players
- 4.4. New Product Launches, By Key Players
- 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships
5. Global Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Recombinant/Conjugate/Subunit
- 5.1.2. Others
- 5.2. Market Analysis, Insights and Forecast - Product
- 5.2.1. SHINGRIX
- 5.2.2. Others
- 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.3.1. Hospital & Retail Pharmacies
- 5.3.2. Government Suppliers
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Recombinant/Conjugate/Subunit
- 6.1.2. Others
- 6.2. Market Analysis, Insights and Forecast - Product
- 6.2.1. SHINGRIX
- 6.2.2. Others
- 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.3.1. Hospital & Retail Pharmacies
- 6.3.2. Government Suppliers
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Recombinant/Conjugate/Subunit
- 7.1.2. Others
- 7.2. Market Analysis, Insights and Forecast - Product
- 7.2.1. SHINGRIX
- 7.2.2. Others
- 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.3.1. Hospital & Retail Pharmacies
- 7.3.2. Government Suppliers
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Recombinant/Conjugate/Subunit
- 8.1.2. Others
- 8.2. Market Analysis, Insights and Forecast - Product
- 8.2.1. SHINGRIX
- 8.2.2. Others
- 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.3.1. Hospital & Retail Pharmacies
- 8.3.2. Government Suppliers
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Recombinant/Conjugate/Subunit
- 9.1.2. Others
- 9.2. Market Analysis, Insights and Forecast - Product
- 9.2.1. SHINGRIX
- 9.2.2. Others
- 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.3.1. Hospital & Retail Pharmacies
- 9.3.2. Government Suppliers
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa Shingles Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Recombinant/Conjugate/Subunit
- 10.1.2. Others
- 10.2. Market Analysis, Insights and Forecast - Product
- 10.2.1. SHINGRIX
- 10.2.2. Others
- 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.3.1. Hospital & Retail Pharmacies
- 10.3.2. Government Suppliers
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. GSK plc
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Moderna Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Jiangsu Recbio Technology Co., Ltd.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Pfizer Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Dynavax Technologies
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Curevo Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.1. GSK plc
List of Tables
- Table 1: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 3: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 4: Global Shingles Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 5: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 6: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 7: North America Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 8: North America Shingles Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 9: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 10: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 11: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: Europe Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
- Table 13: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 14: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 15: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 16: Asia Pacific Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
- Table 17: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 18: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 19: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Latin America Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
- Table 21: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 22: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Product, 2021-2034
- Table 23: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 24: Middle East & Africa Shingles Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
List of Figures
- Figure 1: Global Shingles Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Shingles Vaccines Market Value Share (%), by Type, 2025 & 2034
- Figure 3: Global Shingles Vaccines Market Value Share (%), by Product, 2025 & 2034
- Figure 4: Global Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 5: Global Shingles Vaccines Market Value Share (%), by Region, 2025 & 2034
- Figure 6: North America Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 7: North America Shingles Vaccines Market Value Share (%), by Type, 2025
- Figure 8: North America Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
- Figure 9: North America Shingles Vaccines Market Value Share (%), by Product, 2025
- Figure 10: North America Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 11: North America Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 12: North America Shingles Vaccines Market Value (USD billion), By Country, 2025 & 2034
- Figure 13: North America Shingles Vaccines Market Value Share (%), By Country, 2025
- Figure 14: Europe Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 15: Europe Shingles Vaccines Market Value Share (%), by Type, 2025
- Figure 16: Europe Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
- Figure 17: Europe Shingles Vaccines Market Value Share (%), by Product, 2025
- Figure 18: Europe Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 19: Europe Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 20: Europe Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 21: Europe Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
- Figure 22: Asia Pacific Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 23: Asia Pacific Shingles Vaccines Market Value Share (%), by Type, 2025
- Figure 24: Asia Pacific Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
- Figure 25: Asia Pacific Shingles Vaccines Market Value Share (%), by Product, 2025
- Figure 26: Asia Pacific Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 27: Asia Pacific Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 28: Asia Pacific Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 29: Asia Pacific Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
- Figure 30: Latin America Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 31: Latin America Shingles Vaccines Market Value Share (%), by Type, 2025
- Figure 32: Latin America Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
- Figure 33: Latin America Shingles Vaccines Market Value Share (%), by Product, 2025
- Figure 34: Latin America Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 35: Latin America Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 36: Latin America Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 37: Latin America Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
- Figure 38: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 39: Middle East & Africa Shingles Vaccines Market Value Share (%), by Type, 2025
- Figure 40: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Product, 2025 & 2034
- Figure 41: Middle East & Africa Shingles Vaccines Market Value Share (%), by Product, 2025
- Figure 42: Middle East & Africa Shingles Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 43: Middle East & Africa Shingles Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 44: Middle East & Africa Shingles Vaccines Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
- Figure 45: Middle East & Africa Shingles Vaccines Market Value Share (%), By Country/Sub-Region, 2025
- Figure 46: Global Shingles Vaccines Market Share (%), By Company, 2025
